Alzheimer's disease is the most common form of dementia, affecting millions of people, including family members who often act as caregivers. This devastating disease is believed to account for 8% of total US healthcare spending, with medical and nursing costs amounting to approximately $29 billion. . Alzheimer. The first monoclonal antibody,, to recently receive US FDA accelerated approval for moderate AD is aducanumab. Future therapies could be the first chemical approved to treat AD since 2003. The amyloid (A) pathway is becoming increasingly implicated in the pathogenesis of AD as it has evolved over time from a pathogen to a disease. - biological structure.The approval of aducanumab is based on the reduction of the A-load in the brain, which serves as a direct marker for this signaling pathway. The fully human IgG1 monoclonal antibody aducanumab (BIIB-037) specifically binds to aggregated form A, inhibiting its matrix function and helping to clear plaque. There are three human trials that ended prematurely. Epidemiology, pathophysiology, and risk factors are discussed in this review, and currently aducanumab is the only drug approved for food and drug administration that slows disease progression.